Intra-Cellular Therapies Valuation
Is ITCI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ITCI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ITCI * (MX$1251.41) is trading below our estimate of fair value (MX$6859.32)
Significantly Below Fair Value: ITCI * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ITCI *?
Other financial metrics that can be useful for relative valuation.
What is ITCI *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$6.86b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 12.5x |
Enterprise Value/EBITDA | -48.7x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ITCI *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.9x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$16.0b |
688578 Shanghai Allist Pharmaceuticals | 10.7x | 19.9% | CN¥26.5b |
300765 CSPC Innovation Pharmaceutical | 19.6x | 29.9% | CN¥45.3b |
HCM HUTCHMED (China) | 4.2x | 11.4% | UK£2.8b |
ITCI * Intra-Cellular Therapies | 13.4x | 29.8% | Mex$6.9b |
Price-To-Sales vs Peers: ITCI * is expensive based on its Price-To-Sales Ratio (13.4x) compared to the peer average (9x).
Price to Earnings Ratio vs Industry
How does ITCI *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Sales vs Industry: ITCI * is expensive based on its Price-To-Sales Ratio (13.4x) compared to the Global Pharmaceuticals industry average (2.5x).
Price to Sales Ratio vs Fair Ratio
What is ITCI *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 13.4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ITCI *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$1,504.19 0% | 15.0% | Mex$1,992.34 | Mex$1,079.18 | n/a | 16 |
May ’25 | Mex$1,251.41 | Mex$1,536.59 +22.8% | 15.0% | Mex$2,042.40 | Mex$1,106.30 | n/a | 17 |
Apr ’25 | n/a | Mex$1,388.65 0% | 11.7% | Mex$1,687.67 | Mex$1,086.12 | n/a | 17 |
Mar ’25 | n/a | Mex$1,424.62 0% | 12.1% | Mex$1,728.92 | Mex$1,112.67 | n/a | 16 |
Feb ’25 | n/a | Mex$1,383.40 0% | 14.4% | Mex$1,737.60 | Mex$1,015.04 | n/a | 16 |
Jan ’25 | n/a | Mex$1,325.24 0% | 16.5% | Mex$1,724.00 | Mex$990.02 | n/a | 15 |
Dec ’24 | Mex$1,020.67 | Mex$1,354.13 +32.7% | 17.6% | Mex$1,763.86 | Mex$1,012.91 | n/a | 13 |
Nov ’24 | n/a | Mex$1,398.45 0% | 16.4% | Mex$1,805.35 | Mex$1,065.16 | n/a | 13 |
Oct ’24 | n/a | Mex$1,344.84 0% | 16.2% | Mex$1,709.54 | Mex$1,008.63 | n/a | 12 |
Sep ’24 | n/a | Mex$1,344.84 0% | 16.2% | Mex$1,709.54 | Mex$1,008.63 | n/a | 12 |
Aug ’24 | n/a | Mex$1,316.24 0% | 14.8% | Mex$1,659.05 | Mex$998.82 | n/a | 12 |
Jul ’24 | n/a | Mex$1,318.20 0% | 15.7% | Mex$1,677.71 | Mex$992.93 | n/a | 12 |
Jun ’24 | n/a | Mex$1,336.57 0% | 16.8% | Mex$1,744.66 | Mex$1,032.56 | n/a | 13 |
May ’24 | n/a | Mex$1,320.56 0% | 16.6% | Mex$1,761.67 | Mex$1,006.67 | Mex$1,251.41 | 13 |
Apr ’24 | Mex$1,016.00 | Mex$1,285.04 +26.5% | 18.3% | Mex$1,773.71 | Mex$1,013.55 | n/a | 13 |
Mar ’24 | n/a | Mex$1,265.81 0% | 17.1% | Mex$1,683.57 | Mex$959.45 | n/a | 13 |
Feb ’24 | Mex$897.09 | Mex$1,313.84 +46.5% | 17.1% | Mex$1,745.54 | Mex$1,013.54 | n/a | 13 |
Jan ’24 | n/a | Mex$1,340.67 0% | 17.6% | Mex$1,815.09 | Mex$975.86 | n/a | 13 |
Dec ’23 | n/a | Mex$1,340.67 0% | 17.6% | Mex$1,815.09 | Mex$975.86 | Mex$1,020.67 | 13 |
Nov ’23 | n/a | Mex$1,351.51 0% | 17.4% | Mex$1,794.86 | Mex$977.20 | n/a | 13 |
Oct ’23 | n/a | Mex$1,393.42 0% | 16.8% | Mex$1,813.46 | Mex$987.33 | n/a | 13 |
Sep ’23 | n/a | Mex$1,393.42 0% | 16.8% | Mex$1,813.46 | Mex$987.33 | n/a | 13 |
Aug ’23 | n/a | Mex$1,462.64 0% | 14.3% | Mex$1,860.10 | Mex$1,178.06 | n/a | 13 |
Jul ’23 | n/a | Mex$1,465.33 0% | 14.4% | Mex$1,855.28 | Mex$1,175.01 | n/a | 12 |
Jun ’23 | n/a | Mex$1,422.30 0% | 15.0% | Mex$1,809.87 | Mex$1,146.25 | n/a | 11 |
May ’23 | n/a | Mex$1,414.00 0% | 14.9% | Mex$1,822.73 | Mex$1,154.40 | n/a | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.